Replies to post #105815 on Biotech Values

[mcbio]

Re: ANTH - in-licensing of lead drug

I confirmed my suspicions as ANTH did in fact in-license several of its product candidates, including its lead drug in Phase 3 targeting ACS. See: http://investor.anthera.com/releasedetail.cfm?ReleaseID=424037 which details the in-license agreement with LLY and Shionogi in September 2006.

[DewDiligence]

ANTH’s Varespladib is an anti-inflammatory, not an anticoagulant. To assess whether ANTH is a good investment, I would want to know the outcome of the phase-2 ACS study described in http://clinicaltrials.gov/ct2/show/NCT00743925 .

The clinicaltrials.gov entry says this study finished in Apr 2010, but it does not contain the results.

[drbio45]

anthera

I sat down with the ceo and cfo at a deutche bank conference a few months ago. They had the drug for acs and another one for lupus.

I told them if they only did the trial for lupus and dropped acs I would buy the stock.

they have absolutely no data that tells me that their acs trial has a chance.

the lupus drug looks like a better version of the hgsi compound

[turtlepower]

Regarding ANTH's ACS drug, three words that should scare the bejeezus out of you: RUSSIAN TRIAL DATA